The FDA Changes Its Mind
The day's biggest story is a regulatory reversal. uniQure has won a path toward FDA approval for its Huntington's disease gene therapy, after the agency overturned an earlier rejection in the wake of leadership changes. Ars Technica reports the prior rejection had been characterized as "truly evil," and the about-face came after the departure of an agency official. Investors reacted fast: uniQure shares soared 66% on what Endpoints News called "surprise good news," leaving the company one step closer to marketing a treatment for a devastating neurodegenerative disease that has long lacked good options.
Big Bets on Antibodies and Discovery Platforms
Dealmaking ran hot. Jazz Pharmaceuticals struck a partnership with Canadian antibody developer AbCellera worth up to $4.1 billion, centered on T cell engagers — a class of antibody designed to recruit the immune system against disease. Merck, meanwhile, signed a drug-discovery pact worth up to $510 million with startup Protillion, betting on AI to speed the hunt for new medicines. The throughline: large pharma is paying handsomely for platforms, both biological and computational, rather than just finished drugs.
AI Moves Deeper Into the Lab
Artificial intelligence showed up across the pipeline today. OpenAI says it built a "near-autonomous AI chemist" that improved a difficult reaction used in medicinal chemistry — the painstaking craft of designing and making drug molecules. The NIH announced an AI tool it believes could accelerate antibiotic development, a pressing need given rising resistance. South Korea's LG AI Research agreed to work with D&D Pharmatech on AI-designed next-generation peptide drugs. And Onco-Innovations (ONCO on Cboe Canada, ONNVF on the OTCQB) said it wrapped a pilot pairing AI with quantum computing for drug discovery. Individually incremental, collectively a signal that computational design is becoming table stakes.
Fresh Capital for Fresh Biotechs
The funding window stayed open for early-stage companies chasing hard problems. Vedana Therapeutics emerged from stealth with $46 million in Series A money and an ambitious goal: not merely managing migraines but stopping the headaches entirely, something current drugs can't do. Spot Bio launched with $40 million to develop an mRNA-based therapy for muscular dystrophy, operating across California and China. And Triveni Bio raised a $65 million Series C to push its eczema pipeline toward key clinical readouts — capital arriving at a pivotal moment ahead of data that could make or break the program.
A Cyberattack Hits Novo Nordisk
Finally, a darker note. Novo Nordisk, the Danish maker of some of the world's best-known medicines, has been hit by a cyberattack and is now being extorted, Endpoints News reports. The hackers claim to have stolen the company's AI models and manufacturing recipes — a reminder that as drugmakers pour value into proprietary algorithms and process know-how, those same assets become high-stakes targets. If the claims hold up, the breach underscores that the industry's pivot toward AI brings new categories of risk alongside the upside.
All told, June 17 captured a sector in motion: regulators reversing course, billions changing hands, machines edging into the chemist's bench — and a sharp warning about what's at stake when the crown jewels go digital.